Johnson & Johnson Chief Scientific Officer Paul Stoffels, M.D., will retire at the end of the year, following the lead of CEO Alex Gorsky, who also departs soon. Emile Nuwaysir led Bayer's $1 billion bet on Parkinson's disease, and now he heads up gene therapy biotech Ensoma. Genentech's early cancer research leader Shiva Malek jumps to Novartis' NIBR oncology unit.
by Kyle LaHucik |
May 19, 2021 9:55am Another Novartis R&D leader exits the Swiss pharma giant to take on an executive role at a biotech startup. (Pixabay)
Novartis Gopi Shanker, Ph.D., is the latest R&D leader to exit the Swiss pharma giant as he takes up the helm of chief scientific officer at gene therapy startup Tevard Biosciences.
Shanker follows the exit of Jeff Engelman M.D., Ph.D., who left the Novartis Institutes for Biomedical Research (NIBR) in late-April to form a new cancer biotech, Treeline Biosciences. Days later, Peter Hammerman, M.D., Ph.D., exited to start as chief scientific officer of “molecular machines” biotech MOMA Therapeutics. Both Engelman and Hammerman focused on oncology R&D for the Big Pharma.